BIOD Key Stats
- BIODEL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Yahoo 03/10 16:06 ET
- Nasdaq stocks posting largest volume increases Yahoo 03/07 18:02 ET
- Pre-Open Stock Movers 3/6: (PXLW) (BORN) (SGMO) Higher; (LOV) (XGTI) (SPLS) Lower (more...) Street Insider 03/06 09:31 ET
- On The Fly: After Hours Movers Yahoo 03/05 19:04 ET
- Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product GlobeNewswire 03/05 16:00 ET
- Biodel to Present at the 26th Annual ROTH Conference noodls 03/04 08:49 ET
- Four Biotech Stocks Called to Double Yahoo 02/22 09:06 ET
- Positive Phase I Data from Biodel Yahoo 02/13 16:40 ET
- Positive Phase I Data from Biodel - Analyst Blog Zacks 02/13 11:40 ET
- Biodel (BIOD) Higher on Plans to Advance BIOD-531 on Positive Trial Street Insider 02/12 17:42 ET
BIOD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biodel is up 15.34% over the last year vs S&P 500 Total Return up 24.21%, Endocyte up 35.47%, and Ariad Pharmaceuticals down 63.69%.
Balance Sheet View Statement
Pro Ratings for BIOD
Pro Strategies Featuring BIOD
Did Biodel make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Connecticut
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Biodel, Inc., is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.